Lilly Announces CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint Of Overall Survival

Eli Lilly and Company (NYSE: LLY) today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA™) in combination with ...